Clara Campàs-Moya takes over as head of Advancell
This Catalan biotechnology firm has three solid projects in the clinical phase to treat chronic lymphocytic leukemia, palmar-plantar syndrome and canine atopy.
By Biocat
Clara Campàs-Moya is embarking on a new era as CEO of biotechnology firm Advancell, taking over for Kenneth Weissmahr. With a PhD in Pharmaceuticals and an MSc in Biochemistry and Molecular Biology from the University of Barcelona (UB), she has close ties to this company, where she has worked since 2006. She was previously Executive Vice President and Head of the Business Unit at Advancell Therapeutics.
Noteworthy milestones in her scientific career include the fact that she was one of the co-discoverers of Acadesina, used to treat chronic lymphocytic leukemia, and co-author of the patent for this drug with professor Joan Gil (UB and Idibell). Acadesina is currently in the clinical development phase as ATH001-Acadra. The company also has Cyclostopic-Vet to treat canine atopy in phase IIb and the ATH008 project to treat palmar-plantar syndrome in phase IIb.
Before joining Advancell, Campàs-Moya headed up a research group that focused on developing biomarkers for solid tumors at Barcelona’s Hospital del Mar and was an associate professor in the UB Faculty of Medicine.
Advancell is based at the Barcelona Science Park (PCB) and has a nanomedicine research center at the University of Santiago de Compostela. Previously, since May 2011, the president of the company was Raúl Díaz-Varela. The main shareholders are the Díaz-Varela family and Antonio Vila Casas.